Motesanib diphosphate in progressive differentiated thyroid cancer
ContributorsSherman, Steven I.; Meier, Christoph; Philippe, Jacques
Published inThe New England journal of medicine, vol. 359, no. 1, p. 31-42
Publication date2008
Abstract
Keywords
- Adenocarcinoma, Follicular/drug therapy/secondary
- Adenoma, Oxyphilic/drug therapy/secondary
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Agents/adverse effects/therapeutic use
- Carcinoma, Papillary/drug therapy/secondary
- Female
- Genotype
- Humans
- Indoles/adverse effects/therapeutic use
- Male
- Middle Aged
- Niacinamide/adverse effects/analogs & derivatives/therapeutic use
- Proto-Oncogene Proteins c-kit
- Receptors, Vascular Endothelial Growth Factor/antagonists & inhibitors
- Survival Analysis
- Thyroglobulin/blood
- Thyroid Neoplasms/drug therapy/genetics/pathology
NoteJacques PHILIPPE and Christoph MEIER are participating investigators in the study
Affiliation entities
Research groups
Citation (ISO format)
SHERMAN, Steven I., MEIER, Christoph, PHILIPPE, Jacques. Motesanib diphosphate in progressive differentiated thyroid cancer. In: The New England journal of medicine, 2008, vol. 359, n° 1, p. 31–42. doi: 10.1056/NEJMoa075853
Main files (1)
Article (Accepted version)
Identifiers
- PID : unige:2416
- DOI : 10.1056/NEJMoa075853
- PMID : 18596272
Additional URL for this publicationhttp://content.nejm.org/cgi/content/full/359/1/31
Journal ISSN0028-4793